AlphAIalphai — Financial news for AI agents
MarketBeatMAR 153 min read$OSUR

Altai Capital Management L.P. Has $12.03 Million Stake in OraSure Technologies, Inc. $OSUR

Altai Capital Management L.P. significantly increased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the 3rd quarter, now owning 3,748,836 shares worth approximately $12.03 million and constituting 23.6% of its investment portfolio. This makes OraSure Technologies Altai's second-largest position. Despite strong institutional ownership, analysts have a "Reduce" consensus rating with a target price of $3.00, and the stock recently traded at $2.97.

Original reporting
MarketBeat · MarketBeat
Published Mar 15, 2026, 8:26 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 15, 2026, 9:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Altai Capital Management L.P. Has $12.03 Million Stake in OraSure Technologies, Inc. $OSUR — source image
Source · MarketBeat
Decision brief

The 30-second read

$OSURNeutralLow
01

Why it matters

The increased stake suggests confidence, but the overall cautious analyst sentiment tempers enthusiasm.

02

Market read

Moderate relevance due to institutional stake change and analyst ratings, primarily affecting short to medium-term trading decisions.

03

What to watch

Potential upcoming catalysts or industry-wide shifts could alter the current cautious outlook.

Timing: Medium-term

Background

OraSure Technologies is a biotech firm with recent institutional interest increase, but faces analyst skepticism.

Company-level read

Ticker impact

$OSURNeutralMedium confidence
Context

Significant institutional stake increase and analyst rating

Expected impact

Limited short-term price movement expected; potential slight decline if negative sentiment persists.

Evidence & confidence

Large institutional ownership suggests confidence, but analyst ratings and target prices indicate caution. The stock's current price is near the analyst target, limiting upside potential.

Market effects

Sector

Potential impact on biotech and life sciences sectors due to investor interest

Regional

Limited regional impact; primarily US-focused

Global

Minimal global market influence given the company's size and analyst sentiment

Counterpoint

What could challenge this read

Institutional interest may be a precursor to a potential rally if positive catalysts emerge, such as new product approvals or earnings beats.

Key entities

  • Company
    OraSure Technologies, Inc.

    A biotechnology company specializing in diagnostic and collection devices.

Read at source← All news

Related articles

AUG 13
$OSURMedAI 8/10

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

fool.com6 min
AUG 5
$OSURMed

ORASURE TECHNOLOGIES INC (OSUR): Results of Operations and Financial Condition

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 osur-pressreleaseq22026.htm EX-99.1 Document EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nas

SEC EDGAR 8-K6 min
JUL 22
$OSURMedAI 8/10

OraSure receives Emergency Use Authorization for second generation Ebola test

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

wfmz.com3 min
JUN 11
$OSURMedAI 8/10

OraSure secures FDA clearance for product seen as key to future growth

OraSure (NASDAQ: OSUR) said the FDA has cleared its Colli-Pee at-home urine collection kit, made by subsidiary DNA Genotek, for use with Roche molecular diagnostic systems to identify multiple STIs. OraSure called the clearance important for future growth and noted it also filed for a rapid molecular self-test for Chlamydia and gonorrhoeae. Shares were up over 2% to $4.14.

wfmz.com4 min
JUN 11
$OSURMedAI 8/10

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies said the FDA cleared its Colli-Pee™•Dx urine collection kit (from subsidiary DNA Genotek) for at-home first-void urine collection for Roche cobas 5800/6800/8800 molecular testing. The kit supports tests for Chlamydia, Gonorrhea, Trichomonas vaginalis, and Mycoplasma genitalium, enabling mail-in workflows and decentralized STI screening.

manilatimes.net3 min
AUG 26
$AVEXLowAI 8/10

AVEX Shareholder Alert: October 20, 2026 Lead Plaintiff Deadline in AEVEX Corp. Securities Class Action - Contact Levi & Korsinsky

AEVEX Corp. (NYSE: AVEX) faces a securities class action lawsuit alleging its Board Chairman Brian Raduenz and others concealed a pre-arranged plan to waive a 180-day lock-up period for shareholders. The lawsuit claims misstatements in IPO documents led to a $900 million market value loss for AVEX shareholders in June 2026. The lead plaintiff deadline is October 20, 2026, according to Levi & Korsinsky, LLP.

prnewswire.com2 min